This earnings call was originally scheduled to take place on Thursday, September 22, 2022 at 4:15 pm (Eastern). The earnings call to take place on Wednesday, September 21, 2022 at 4:30 pm (Eastern) replaces the originally scheduled event.
LAS VEGAS and VANCOUVER, SEPTEMBER 19, 2022 - TAAT® GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT®”) is pleased to announce that it will host an earnings call on Wednesday, September 21, 2022 at 4:30 pm (Eastern) led by its Chief Executive Officer Michael Saxon and its Chief Financial Officer Joel Dumaresq. During this call, Mr. Saxon and Mr. Dumaresq will provide an overview of the Company’s financial performance during its Fiscal Third Quarter of 2022 (three-month period ended July 31, 2022, referred to herein as “FQ3 2022”), and summarize the Company’s business activities during the same period. A full recording of the call will be published on the Company’s website shortly after the event’s conclusion. Investors may submit questions in advance of Wednesday’s TAAT® FQ3 2022 earnings call by email to email@example.com.
TAAT® Chief Executive Officer Michael Saxon commented, “After officially joining the TAAT® management team in June, I am pleased at the progress we have made in such a short time. This marks the first fiscal quarter in which ADCO is part of our operations. Additionally, we have made great progress with TAAT® in our focus markets, and look forward to sharing our progress with investors on Wednesday.”
At 4:30 pm (Eastern) on Wednesday, September 21, 2022, TAAT® will be hosting its FQ3 2022 earnings call led by CEO Michael Saxon and CFO Joel Dumaresq. A full recording of the call will be published shortly after its conclusion.
Readers using news aggregation services may be unable to view the media above. Please access SEDAR or the Investor Relations section of the Company’s website for a version of this press release containing all published media.
The TAAT® FQ3 2022 earnings call is open to the public, free of charge. Registration for the TAAT® FQ3 2022 earnings call can be accessed by clicking on the following link: https://services.choruscall.ca/DiamondPassRegistration/register?confirmationNumber=10020247&linkSecurityString=186dd6c341
Readers using news aggregation services may be unable to view the FQ3 2022 earnings call registration link originally published in this press release. Readers who cannot see a link above can access the version of this press release containing the link on the Company’s website or filed on SEDAR.
Please note that the Company’s management may exercise discretion with respect to choosing whether or not to answer questions that may potentially involve confidential, proprietary, or competitive information. All questions must be submitted prior to the TAAT® FQ3 2022 earnings call.
For clarity, this earnings call was originally scheduled to take place on Thursday, September 22, 2022 at 4:15 pm (Eastern) as announced in the Company’s July 19, 2022 press release. The TAAT® FQ3 2022 earnings call to be held on Wednesday, September 21, 2022 at 4:30 pm (Eastern) officially replaces the originally scheduled event.
On behalf of the Board of Directors of the Company,
TAAT® GLOBAL ALTERNATIVES INC.
Michael Saxon, CEO and Director
For further information, please contact:
TAAT® Investor Relations
THE CANADIAN SECURITIES EXCHANGE (“CSE”) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.
About TAAT® Global Alternatives Inc.
TAAT® develops, manufactures, and distributes alternative products in categories such as tobacco, hemp, kratom, and other emerging CPG segments. Its flagship product is a nicotine-free/tobacco-free combustible with a patent-pending base material formulation, sold in several thousand U.S. stores. With over CAD $80 million in overall gross revenue annually, TAAT®’s facilities include an operations centre in Nevada, as well as a distribution centre and multiple convenience stores in Ohio.
For more information, please visit http://taatglobal.com.
This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking information and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur, or be achieved. Forward-looking information in this news release includes statements regarding the anticipated performance of TAAT® in the tobacco industry, in addition to the following: Occurrence of the TAAT® FQ3 2022 earnings call on Wednesday, September 21, 2022 as detailed in the press release. The forward-looking information reflects management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking information. Although the Company believes that the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed timeframes or at all. Factors that could cause actual results or events to differ materially from current expectations include: (i) adverse market conditions; (ii) changes to the growth and size of the tobacco markets; (iii) changes to the regulatory landscape applicable to the Company's business; and (iv) other factors beyond the control of the Company. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking information. The forward-looking information included in this news release are made as of the date of this news release and the Company expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law.
The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company’s products will vary from person to person. No claims or guarantees can be made as to the effects of the Company’s products on an individual’s health and well-being. The Company’s products are not intended to diagnose, treat, cure, or prevent any disease.
This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by the Company with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with the Company is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.
Statement Regarding Third-Party Investor Relations Firms
Disclosures relating to investor relations firms retained by TAAT® Global Alternatives Inc. can be found under the Company's profile on http://sedar.com.